92nd annual meeting of the American association for cancer research

Expert Opinion on Investigational Drugs

Volumn 10, Issue 6, 2001, Pages 1173-1193

  Buser, C ^a   Takaki, T ^a   Sepp Lorenzino, L ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Anti angiogenesis; Cancer; Farnesyl transferase inhibitors; Kinase inhibitors

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; 6 CYCLOHEXYLMETHOXY 2 (4 SULFAMOYLANILINO)PURINE; 6 O CYCLOHEXYLMETHYLGUANINE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BCR ABL PROTEIN INHIBITOR; BIOLOGICAL MARKER; BMS 239091; BMS 250904; CP 609754; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; DIMETHYLALLYLTRANSFERASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; GLYCOPROTEIN P; IMATINIB; L 778123; LONAFARNIB; OSI 744; PACLITAXEL; PNU 252808; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN INHIBITOR; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RADIOSENSITIZING AGENT; TIPIFARNIB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BONE MARROW TOXICITY; CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG EFFICACY; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TOXICITY; HUMAN; MEDICAL EDUCATION; MEDICAL INFORMATION; MEDICAL LITERATURE; MEDICAL SOCIETY; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRENYLATION; RADIOSENSITIZATION; RAT; SYMPOSIUM;

ANIMALS; CARRIER PROTEINS; CLINICAL TRIALS; DIMETHYLALLYLTRANSTRANSFERASE; ENZYME INHIBITORS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASMS; PIPERAZINES; PYRIMIDINES; SOCIETIES, MEDICAL; UNITED STATES;

EID: 0034988579     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.6.1173     Document Type: Article

References (102)

1. Inhibition of HDJ2 protein farnesylation in peripheral blood mononuclear cells as a pharmacodynamic endpoint in a Phase I study of R115777 and gemcitabine
2. Evaluation of biochemical markers of protein farnesylation in human tumor specimens following treatment with oral SCH 66336, an inhibitor of farnesyl protein transferase
3. A Phase I/II study of the farnesyl transferase inhibitor (FTI) SCH66336 with paclitaxel in patients with solid tumors
4. Preclinical and Phase I trial results of the farnesyltransferase inhibitor (FTI), L-778,123 and radiotherapy
5. Effects of R115777, a farnesyl transferase inhibitor (FTI), on methylnitrosourea (MNU)-induced mammary cancers: Role of Ha-Ras mutation
6. Preclinical antitumor and pharmacodynamic studies with the farnesyl transferase inhibitor (FTI) R115777
7. The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein
8. SCH66336, a farnesyl transferase inhibitor, decrease the levels of angiogenic growth factors in various tumor models
9. The FT inhibitor BMS-214662 selectively targets the non-proliferating cell subpopulation in solid tumors - Implications for a synergistic therapeutic strategy
10. Role of mitochondria in apoptosis induced by BMS-214662, an unusually apoptotic farnesyltransferase inhibitor
11. Potential Dual Mechanism of action for BMS-214662, a member of the benzodiazepine class farnesyltransferase inhibitors
12. Preclinical toxicity of LB 42908 (NSC-712392), a novel farnesyl transferase (FTase) inhibitor proposed for the treatment of cancer
13. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase
14. Constitutively activated Akt-2 blocks the ability of FTI-2148 to inhibit the growth and to induce apoptosis of the human ovarian carcinoma OCVAR3 in nude mice
15. FTI-2153 inhibits bipolar spindle formation in human cancer cells: A mechanism for FTI-induced mitotic arrest
16. Targeting Ki-Ras for cancer therapy: Evaluation of combinations of farnesyl and geranylgeranyl transferase inhibitors in pre-clinical models
17. LC/MS characterization of Ki-Ras prenylation after treatment with selective and dual inhibitors of FPTase and GGPTase-I in pre-clinical mouse models
18. Geranylgeranyltransferase I (GGTase I) inhibitors induce mammary tumor regression in oncogenic H-Ras transgenic mice: Validation of GGTase I as a cancer therapy target
19. Upregulation of RhoB transcription, not inhibition of RhoB prenylation, as a potential mechanism by which farnesyltransferase and geranylgeranyltransferase I inhibitors suppress human tumor growth
20. Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice
21. Inhibition of RhoB geranylgeranylation is critical for GGTI-298 disruption of cytoskeleton organization and induction of p21WAF in immortalized murine fibroblasts
22. The farnesyltransferase inhibitor L-744,832 reduces hypoxia in tumors expressing activated H-ras
23. Farnesylated RhoB increases cell survival after irradiation of NIH-3T3 cells
24. Effects of protein palmitoylation inhibitors on RAS palmitoylation and the Ras-mediated MAPK and AKT pathways
25. Isolation of T24 proteins covalently modified by palmityltransferase inhibitors
26. Human RAS converting enzyme (hRCE1) endoproteolytic activity on RAS derived peptides
27. Inhibition of RAS converting endopeptidase (RCE) modulates RAS processing and function
28. The CDK2/cyclin A inhibitor PNU-252808 blocks cell cycle progression and induces apoptosis in tumor cells both in vitro and in vivo
29. Aminothiazole inhibitors of cyclin-dependent kinase (CDK) 2 block cell cycle progression and induce apoptosis
30. Discovery and development of 2-amino-5-thioalkylaryl thiazoles as inhibitors of cyclin-dependent kinase 2
31. Structure-based design of potent inhibitors of CDK1 and CDK2 2
32. Cellular pharmacology of a novel potent CDK1 and CDK2 inhibitor
33. Novel CDK2 inhibitors and their effects on the cell cycle in MCF-7 tumor cells
34. Demonstration of in vivo efficacy of CGP79807 on cell cycle dependent kinases (CDK), cycle progression and onset of apoptosis in a hollow-fiber model in mice
35. Novel indolinone compounds as potent cyclin-dependent kinase 2 inhibitors
36. Different binding modes of two structurally similar CDK2 inhibitors
37. Inhibition of cyclin dependent kinase 2 (CDK2) by SU9516 prevents dissociation of retinoblastoma protein (pRb) from E2F
38. Indirubins, novel potent inhibitors of cyclin-dependent kinases, inhibit the growth of human xenograft tumors
39. CDK-604: A highly potent oxindole inhibitor of CDK1 (Cdc-2/cyclin B)
40. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs
41. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors
42. and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
43. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
44. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor
45. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy
46. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents
47. ZD 1839 ('Iressa') as an anticancer agent
48. ZD 1839 ('Iressa'), a novel EGF receptor tyrosine kinase inhibitor (EGFR-TKI), inhibits the growth of EGFR- and ErbB2-overexpressing tumors in vivo
49. Influence of epidermal growth factor receptor (EGFR) expression, p53 and ras mutation status on the antiproliferative effects of ZD 1839 ('Iressa')
50. Ovarian clear cell adenocarcinoma: Establishment of a new treatment strategy
51. Growth inhibitory effects of ZD 1839 ('Iressa') on human bladder cancer cell lines
52. Combination of ZD 1839 ('Iressa'), and EGFR-TKI and radiotherapy increases antitumor efficacy in a human colon cancer xenograft model
53. ZD 1839 ('Iressa'), and EGFR selective tyrosine kinase inhibitor, enhances activity of taxanes in Bcl-2 overexpressing, multidrud resistant MCF-7 ADR human breast cancer cells
54. Inhibition of EGFR-tyrosine kinase by ZD 1839 ('Iressa') leads to antiproliferative and antiangiogenic effects in human GEO colon cancer xenografts, in combination with paclitaxel
55. Cooperative inhibitory effect of ZD 1839 ('Iressa') in combination with trastuzumab on human breast cancer cell growth
56. Sequence-dependent cytotoxic effects of binary and ternary combinations of ZD 1839 ('Iressa') with 5-fluorouracyl (5FU) and/or cisplatin (CP): Application in head and neck cancer cell lines
57. Specific inhibition of EGFR tyrosine kinase with ZD 1839 ('Iressa') combined with a protein kinase a antisense and the novel taxane IDN5109 causes cooperative inhibition of tumor growth and angiogenesis
58. Epidermal growth factor receptor tyrosine kinase inhibition by ZD 1839 ('Iressa') blocks oestrogen-stimulated proliferation and progesterone receptor expression in human breast epithelium
59. Inhibition of the epidermal growth factor receptor activation and signaling by OSI-774, a novel EGFR inhibitor, in clinical specimens of head and neck carcinoma
60. Pharmacokinetic/pharmacodynamic profile of the EGF-receptor inhibitor PK1166 in nude mice bearing NCI H-596 lung tumor xenografts
61. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies
62. Comparison of the tyrosine kinase activities of Erb B-2 and EGFR: Binding of selective enzyme inhibitors can be modulated by aniline substitution in the quinazoline series
63. The discovery of a new anti-cancer agent GW2016: A potent dual EGFR/ErbB-2 tyrosine kinase inhibitor
64. GW2016, a dual inhibitor of ErbB-2 and EGFR tyrosine kinases: Effects on receptor tyrosine autophosphorylation, downstream signaling intermediaries, and in vivo anti-tumor activity
65. The effects of the novel EGRF/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and transformed cell lines
66. Antitumor activity of GW2016 in the EGFR positive human head and neck cancer xenograft, HN5
67. Anti-tumor activity of GW2016 in the ErbB-2 positive human breast cancer xenograft, BT474
68. New paradigms for the treatment of cancer: The role of anti-angiogenesis agents
69. Antiangiogenic strategies and agents in clinical trials
70. Decrease of plasma PSA levels and inhibition of tumor growth by ZK 222584/PTK787 - Surrogate marker for a xenograft tumor model
71. Correlation between inhibition of bFGF-induced angiogenesis in an in vivo growth factor implant model and inhibition of tumor growth in tumors exhibiting different upregulation of bFGF for a series of selective VEGF inhibitors
72. Dynamic contrast enhanced magnetic resonance imaging as a surrogate marker of efficacy in a Phase I trial of a VEGF receptor kinase inhibitor
73. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model
74. ZK 222584/PTK787, a specific inhibitor the VEGF receptor kinases, primarily reduces tumor microvessels and induces changes in dynamic MRI measurements in murine renal cell carcinoma
75. Structure activity relationship and in vivo efficacy of indole-quinazolines, a novel series of selective and orally active inhibitors of VEGF receptor tyrosine kinase activity (Flt-1 and KDR)
76. ZD6474: Design, synthesis and structure activity relationship of a novel, orally active VEGF receptor tyrosine kinase inhibitor
77. Dynamic contrast-enhanced MRI study of human tumor xenografts treated with the VEGF signaling inhibitor ZD 6474
78. MRI evaluation of the effects os ZD6126 on tumor vasculature
79. Assessment of the novel tumor vascular targeting agent ZD6126 by non-invasive multi-gradient echo MRI
80. Concomitant SU516 treatment increases the effect of fractionated radiotherapy on glioblastoma U-87
81. Flt-1 tyrosine kinase inhibition results in delayed wound healing response and anti-tumor activity: Introducing a novel method to screen anti-angiogenic compounds
82. Growth inhibition of Ewing's sarcomas following treatment with anti-tyrosine kinase receptor compounds
83. Inhibition of the VEGF, PDGF, and bFGF signaling pathways with SU6668 decreases the growth rate of human neuroblastoma xenografts
84. SU6668, a broad spectrum antiangiogenesis inhibitor, is active in diverse models of tumor growth and metastasis
85. SU6668 inhibits the growth of subcutaneously implanted and liver metastatic human colon carcinoma xenografts in severe combined-deficient mouse
86. In vivo mechanism of action and target modulation studies of SU6668, a broad spectrum antiangiogenesis inhibitor
87. Inhibition of ascites and tumor spread of human ovarian carcinoma xenografts by oral administration of SU6668, a potent inhibitor of tyrosine kinase activities
88. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration
89. Anti-angiogenesis therapy revisited: Targeting both paracrine and autocrine angiogenic signaling pathways with neutralizing antibodies to VEGFR2 is essential to inhibit tumor growth
90. SU5416 and SU6668 inhibit tyrosine kinase mediated survival signals and induce apoptosis in myeloid leukemia cells
91. Novel tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells
92. Use of in vivo intracellular signaling as a surrogate marker for anti-angiogenic activity in colon cancer liver metastasis
93. Inhibition of angiogenesis and tumor growth by AG13925, a small molecule inhibitor of vascular endothelial growth factor receptor tyrosine kinase
94. Potent in vitro inhibition of VEGF-mediated endothelial cell survival and KDR signaling by AG13925, a novel small molecule inhibitor of the VEGF tyrosine kinase receptors
95. An orally active inhibitor of VEGF receptor tyrosine kinase with potent anti-tumor activity
96. Involvement of VEGF in bFGF-induced angiogenesis
97. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma
98. Phenotypic diversity of organ-specific endothelial cells
99. Blockade of EGF-R signaling inhibits resorption of bone and growth of human prostate cancer cells implanted into the tibias of nude mice
100. Blockade of PDGF-R signaling by STI-571 inhibits angiogenesis and growth of human prostate cancer cells implanted in the bone of nude mice
101. Blockade of epidermal growth factor receptor (EGF-R) signaling as treatment for pancreatic cancer liver metastases in nude mice
102. Combined treatment of HNSCC tumor xenografts with antiangiogenic endostatin and EGFR antisense gene therapy